Developing molecular markers to select the anti-cancer therapies in metastatic colorectal cancer

Developing molecular markers to select the anti-cancer therapies in metastatic colorectal cancer - Molecular markers to select the anti-cancer therapies in metastatic colorectal cancer

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000004298

Enrollment

150

Registered

2010-09-30

Start date

2005-12-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colorectal cancer

Interventions

Oxialiplatin-based therapies (FOLFOX, CapeOX), Irinotecan-based therapies (FOLFIRI, IFL, IRIS), Molecular targeting therapies (Bevacizumab, Cetuximab) Mutational analyses of various genes

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Histologicaly defined colorectal cancer 2. Patients who have recieved second or subcequent lines of treatments. 3. Patients with a target resion. 4. ECOG performance status 0, 1 or 2

Exclusion criteria

Exclusion criteria: 1. Patients without informed consent. 2. Formalin-fixed, paraffin-embedded (FFPE) samples of tumor tissue are not available

Design outcomes

Primary

Measure	Time frame
Association between the response rate of anti-cancer drug therapies and genetic alterations	—

Secondary

Measure	Time frame
Association between the prograssion free survival of anti-cancer drug therapies and genetic alterations	—

Countries

Japan

Contacts

Public ContactHideki Shimodaira

Institute of Development, Aging and Cancer, Tohoku University Department of Clinical Oncology

hshimoda@idac.tohoku.ac.jp022-717-8547

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026